LV10178B - Method of preparation of physiologically acceptable, stable in storage protein composition - Google Patents
Method of preparation of physiologically acceptable, stable in storage protein composition Download PDFInfo
- Publication number
- LV10178B LV10178B LVP-93-470A LV930470A LV10178B LV 10178 B LV10178 B LV 10178B LV 930470 A LV930470 A LV 930470A LV 10178 B LV10178 B LV 10178B
- Authority
- LV
- Latvia
- Prior art keywords
- preparation
- human protein
- erythropoietin
- stable
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
LV 10178
OnncaHMe Πρθ,π,ΜθτοΜ HacTOflūļero μ3ο6ρθτθημη ηβληθτοη cnocoč nojiyxie-HHfl CTa()HJIbHHX, HeHMMyHOreHHbIX, $H3H0JI0rH^eCKM χοροπίο COBMee-THMbIX, paCTBOpeHHbDC HJM CytfJĪHMatļKOHHO BHCymeHHHX raJieHOBbIX Κ0ΜΠ03ΜΙ1ΜΚ M3 ^θϋΟΒβ^βΟΚΗΧ ΠρΟΤΘΗΗΟΒ (6eJIK0B), B OCOČeHHOCTH 3pHTp0n0H3THHa. 2
KeJiOBenecKne προτθΗΗΚ (6θλκη) npe^CTaBJinioT co6oM ayToreH-HBie, MMeK)mneCH TOJIbKO B He3HaTļMTeJIbHbīX KOJIHHeCTBaX, ΠρΟΤΘΗΗΗ, Kan, HanpHMep, TKaHeBbin njia3MoreHHbiH aKTHBaTop ( /-PA), CTpenT0KHHa3a, ypoKHHa3a, ΗΗτερφεροΗ, CTHM-yjiHpyKJnpie pa3JiKHHbie KOJIOHHH $aKTOpbI (CST) HJIH 3ρΗΤρ0Π0Η3ΤΗΗ (EPO). Ka npHMepe ΞΡ0, KOTopbii! npeflnotiTHTeJibHO Hcnojib3yeTCH b cocTaBe, K3o(5pe-τβΗΜβ noHCHHeTCfl noflpoČHee. 3ρκτροποΗ3ΤΗΗ (EPO) npe^CTaBJineT cočon ιυτπκοπροτεΗΗ, ko-TopbiM CTMMyjiHpyeT 0i5pa30BaHHe reMorjioČHHa, οοοτβθτοτβθηηο, ορκτρoijļHτob b kocthom M03ry. 3τοτ ΛκποπροτθΗΗ očpa3yeTCfl TJiaB-HbiM odpa30M b nonKax, b oneHb He3HaqHTeJibHbix KOJiHHecTBax Haxo-AHTCH B CbIBOpOTKe Η ΠρΗ φΗ3Η0ϋ0ΓΗ^β0ΚΗΧ yCJIOBHHX HaCTHHHO BbJ- ^eJineTCH b uove. OTcyTCTBHe EPO npn nonenHOft HeflocTaTOHHOCTH o6ycJiOBJieHo peHajībHoK aHeMHew. Ejiaro^apn ββθ,π,θηηιο EPO β Φηβηολογηϊιθοκηχ KOJIHHeCTBax, T.e. HeCKOJIbKO MHKpOrpaMM, 3a 0,ū,Hy HJIH HeCKOJĪbKO ,n;03Hp0B0K, mo}kho CHOBa B036y3KflaTb B TaKHX cjiyyanx o6pa30BaHwe spHTpoiļHTOB. TaK Kan opraHH3M qyBCTBKTe;ibHO pearwpyeT ywe Ha He3HaqHTeJIbHHe Η3ΜΘΗβΗΗΗ fl03H, TO ,Iļ03Mp0BKa flOJDnHa ČbITb TOtJHO B0cnp0H3B0,n,KMa. OdbBiHO EPO niTBeKiņipyī)T hjih BHyTpnMtimemM hjih BHyTpHBeHHO B BHfle ΒΟβΗΟΓΟ paCTBOpa HJIH BBOflHT Β ΒΗ,Π,β pacnbl-JineMoro pacTBopa nepe3 cjiH3HCTyio o(5ojionKy Hoca.
OflHaKO, H3B0CTHO, HTO EPO, Η ΗΜΘΗΗΟ KaK npeftfle ΒΟΘΓΟ ΠΟ-Jiy^eHHbiH H3 tieJiOBe^ecKOft mohh προ^κτ (MLyaice h p$.t Blol.
Caem . T.25, 5558-5564, 1977), KaK Taranē nojiyHaeMbie Me&fly τθμ nyTeM ΓΘΗΗΟΗ ΗΗ/ΚΘΗβρΗΗ προ^κτΗ (BOKC 85-02610), B BOflHOM pac-TBOpe HecTaČHJībHbi h flaaie npn xpaHeHHH npn - 80°C HacTynaioT 6ojibiiiHe ποτθρκ aKTHBHOCTH. 3th o(5a BH^a προ,πγκτοΒ OTJiHnaiOTCH HeCKOJIbKO ΠΟ o6pa3y rJIHK03HJIHp0BaHHH Η ΓΙΟ aKTHBHOCTH, ΠρΗΜΟΘ cpaBHeHHe c coflepmaiiļHMCH β ΟΗΒοροτκβ EPO ^o chx πορ ηθη3ΒΘΟτηο.
3th ποτθρκ aKTHBHOCTH CBflHTCH, c ο,π,ηοη CTopoHbi, κ pa3py-ιπθήηκ) (pa3Jio}KeHHK)) EPO 3a cneT KaTajiHTHnecKHx Θφφεκτοε ποΒβρχ-hocth cjiy®aiEļHX flJin xpaHeHHH aMnyji, djiaro^apH cjieflaM τηκθληχ MeTaJiJiOB’, KHCJiopofly B03,nyxa h τ.β., c ,ņpyroH ctopohh, o^HaKO, Taranē 3a cneT OTJmeHHH EP0-MOJieKy;i Ha CTeHKax cocy,]ļa, npnneM Taranē Μοτκβτ npoHCxoflHTb nacTHHHO fleHaTypaiļHH. TaK,KaK CKa3aH0 Bbllīie, B Kam^OH Α03Ηρ0Β0ΗΗ0Γί eflHHHIļe flOJTJKHbl CO^epmaTbCH TOJIbKO HeCKOJIbKO MHKporpaMMOB, noTepn sa chct aflcopčijHH yme cnycTH LV 10178 κοροτκοθ BpeMH xpaHeHMH MoryT 6bitb 3HaqHT6JibHHMH. B eBponeftCKOM naTeHTe A-I78 576 ri03T0My onncano μηγη(5ηρο-BaHue 3τογο οτιιοικθηηη Ha θτθηκθχ cocy^a diiaro^apn ,π,ο6θβκθ no-jrnMepHbix θοθ,π,μηθηη^ , nan ajibdyMHH cbiBopoTKM ηθιιοβθκθ hjih Kpyn-Horo poraToro θκοτθ, JieijHTMH, jļeKCTpaH, iļeJDnojio3a, nojiMSTMJieH-rJIMKOJIb H T.fl. , H TaKHM 0(5pa30M, ,Π,ΟΘΤΗΙΚΘΗΜΘ CnyCTH npHMepHO 2 qaca xpaHeHμη npn 20°C odHapy®eHHH EPO b KOJiHtiecTBe 75-98%, b npoTMBonojio?KHOCTb qeMy odHapy7KHBaioT tojibko 16% 6e3 τΆκοϋ ,π,ο-6aBKM. IIpM 3T0M, ΒΓφΟΗΘΜ, H3MepHJĪ0Cb TOJIbKO 0<5Hapy®eHHe paflHO-aKTHBHOfi MapKHpoBKM (^C), Tan ητο bth οπμτβι ηηηθγο ηθ γοβορητ o CTa6HJiH3aiļHH EPO οτ pa3Jio®eHHH.
CorJiaCHO HafifleHHOMy HBMH, CTa(5HJIH3aiJHH Β ΤΘ^ΘΗΗΘ flJIHTeJIb-ΗΟΓΟ ΒρΘΜΘΗΗ C ΠΟΜΟΠ^ΒΚ) ΤΘΚΗΧ CpeflCTB, OflHaKO, HeJIb3fl flOCTH-raTb, T.e. EPO-aKTHBKocTb b TecTe Ha mkwh CHJībHO na.n.aeT, κ TOMy κθ 3th cpe^cTBa πρκ ηηΦθκι1ηη βη3ηβθιοτ HMMyHoreHHbie pe-aKU,HH.
Ms eBponeKcKoro naTeHTa A-I7S 665, ,π,θιιθθ, η3βθθτηβι "cTadn-jix3aTopbi”, β οοο6θηηοοτη fljiH cy(5jiHMaijpīOHHO BbicymeHHbix EPO-npe-napaTOB. Hapn^y c ποιιημθρηημη BenļecTBaMH Π3Γ 4000, stejiaTHHoft h ,n,eKCTpaHOM 40, Ha3BaHbi pasjiHHHbie caxapa h MHoro3biaqHbie cimp-Tbi, flamme πρκ okhcjibhhh MOHocaxapH(n,H; aMHHOKHCJioTbi; HeopraHH-qecKne cojim h THOJibHbie θοθ,π,ηηθημη. KoMdHHauļHH sthx BeiiiecTB c qeJiOBeqecKMM cbibopoto^hhm ajibdyMHHOM, jKeJiaTMHoft h ^eKCTpaHOM TaKTKe yKa3aHH. Tarate β θτομ JiHTepaTypHOM κθτοχιηηκθ onpe^ejra-θτοη TOJIbKO o6Hapy®eHxe pajļHoaKTHBHOCTeM cnycTH 2 Mecniļa xpa-ηθηηη cy6jiHMaiļMOHHO BbicymeHHbix προ^κτοΒ. 0ho yKa3HBaeTCH paB-HbM 87-99%, b npoTHBonoJiOKHOCTb 60% 6e3 flodasoK. Tan KaK jiho- $HJIH3HpOBaHHbIH MaTepnaJI HCn0JIb3yeTCH ΗΘΠΟΟρβ,Π,ΟΤΒΘΗΗΟ nocjie ΠΟ- jiyqeHHH β KanecTBe CTaHflapTa, το ηθ yKa3aH0, mme eiiļe ποτΘρπ aKTHBHOCTM πρκ πρΗΓΟτοΒϋβΗΗΗ npenapaTOB. Tax®e sth npenapara odJia^aioT bbicokoh riOTepen aKTHBHOCTH β τθοτθ Ha Mbimax.
Ilo3TOMy (5biJia nocTaBJieHa 3a,n;aqa θο3,π£ηηη χοροιπο οοβμθθτη-μογο EPO-npenapaTa, κοτορυΛ CTadHJieH πρκ xpaHeHHH, t.k. cox-paHfleT "hH BMBO" aKTHBHOCTb, ΗΘ ΠρΗΒΟ,Π,ΚΤ K aACOp(5]j;HHM Ha ΘΤΘΗ-Kax aMnyji hjih mnpHiļOB h Jierao μο«θτ nepeBOflHTbCH β HH,B6KiļHpye-Myio $opMy. 4
HeojKHflaHHO 3Ta samana pemaeTCH ČJiaroflapn noflpoČHee.oxapaK-TepH30BaHH0W B $OpMyJie Η3θ6ρ6ΤβΗΗΗ KOMČHHaiļHM pa3JIHHHBIX ΚΟΜΠα-ηθητοβ. Kan noKa3ajiH Hamn Όπβιτβι, HH1nlHBH(n1yajibHBie BemecTBa bthmh CBOMCTBaMH He oČJiaflaioT hjih o^Jia^aiOT tojibko b He3HanHTeJibH0H Mepe.
Pemaromeft ^jih CTaČHJiHsaiļHH ηβληθτοη ^odaBKa μοηθβηηβι h pa3-jihhhbix slmhhokhcjiot . MoqeBHHa ncnojib3yeTCH b KOJinnecTBe 5-50 γ/ji πρθ,π,πο^τΗΤθΛΒΗΟ 10-15 γ/ji. B KatieCTBe aMHHOKHCJiOT cJie,nyeT Ha3-BaTb, HanpHMep, rJiHiļHH, L-ajiaHMH, L-aprHHHH,L-jieHiļKH, L-H30Jieiī-[ļHH,I-2-$eHKJiajiaHHH, IrrjiyTaMHHOBaH KHCJiOTa mm L-TpeoHHH. Ομθ-CH pa3JIHtIHBIX aMHHOKHCJiOT, nO-BHlD1KMOMy, ΚΜΘΙΟΤ OCOČeHHO Πρθ,Π,ΠΟη- TMTejibHBii/Γθφφβκτ. Mx Mcnojib3yī0T β KOJiHT-iecTBax 0,5-50 γ/ji, πρΘ,π;-nOHTKTeJIbHO 1-20 γ/ji, npnqeM' 0(5mee KOJIHHeCTBO flOJDKHO COCTaBJIHTb npeflnoqTHTeJibHo 5-25 γ/ji. .Iķuiee, ηθο(5χοαημ $η3ηολογη^θοκη οοβμθοτημβιη 6y$ep, κοτορΒίβ E ΗΘΟβχΟ^ΜΜΗΧ JĻJIH ΜΗΊΒΘΚΙ1ΜΟΗΗΒΙΧ paCTBOpOB H63HaHKTΘJIbHBIX ΚΟΗΙ1ΘΗ-
TpaiļHHx (npHMepHO 20-100 mmojib/ji) ycTaHaBJWBaeT Heo(5xoflHMyK> fljin E?0 pH-oČJiacTb 6,5-7,4, e οοο(5θηηοοτμ 7,0-7,2. KpOMe $oc$aTHbix βγφβρΟΒ πρΗΜβΗΗΜΗ τβκηθ rjiHiņiHaT, Kap6oHa.T, ijHTpaT v, ,npyrHe, np>meM B KaqeCTBe ΓφΟΤΚΒΟΗΟΗΟΒ MO?yT CJiyHHTb, ΚρΟΜΘ HOHOB HaT-pxH m KajiHfl, Tanste hohbi aMMOHHH . By$epKpoBaHHe flonojiHHTeJibHo BBISBIBaeTCH COflepJKaiIļMMHCH aMKHOKHCJIOTaMH. rīpMJīMnaHKe EP0 κ CTennaM aMnyji m mnpHijaM cyni,eCTBeHHO chm-saeTca 3a cneT flotfaBKH He3HaqKTejibHHx KOJinnecTB ^eTepreHTa.
Tax Kan npenapaT ftOJDKeH ηρθ,π,ποΗΤκτΘΐίΒΗΟ ββο,π,ητβοη nyTeM ΗΗΈβκ-φϊΚ, 3T0 BeiHļeCTBO flOJDKHO (JBITb φ)Η3Η0ΙΙ0ΓΗΗΘ0ΚΗ, ' Β OCO(5eHHOCTH BHyTpHB8HH0, COBMeCTHMO. 0Ka3BlBaK)TCH ΠρΗΓΟ^ΗΒΙΜΗ KOHIļeHTpaiļHH 0,05-5 γ/ji, β ocodeHHOCTH 0,1-0,5 r. Ηθκοηηβιθ CMaHHBaTejiH,
Kax pa3JmqHBie βη,π,βι noJiHKaKporojiOB , b ocoSeHHOCTH ποιιηθτηιιθη-cop6xTaHJiaypaT (Tbhh 20 hjih 80) mm copČHTaHTpnojieaT ( ^pan 35 HJIH 80) HJIH nOJIHrJIHKOJieBBIH θφπρ rJIHIļepHHOJieHJIOBOK KHCJIOTBI (LctirajU L^) 0Ka3BiBaeTCH πρηγο^ηβιμη jļJiH stoM iļejin, ojļHaKO, β paBHOH Mepe MoryT HcnojibsOBaTbcn ,npyrHe coBMecTHMBie BemecTBa.
AjIH yMeHbineHHH BJIHHHHH Ha EP0 HOHOB THKeJIBDC MeTaJIJIOB, KO-τορΒίβ notiTH ηθη36θ}κηο yBJieKaioTCH πρκ odpačoTKe, HanpHMep, H3 Hcnojib3yeMBix MeTajuiHHecKHX HHCTpyMeHTOB, ftajiee, 0Ka3BraaeTCH πρΗΓο^ΗΒίΜ flodaBJiei-me pacTBopa 0,01-5 γ/ji pacTBopHMOH Kajībiļne- LV 10178 ΒΟΗ COJIH, npe,n,noqTHTeJIbHO npKMepHO 0,02-0,2 r/jl, ΧΠΟρΗ,Π^ KaJīb-iļHH. Taicsce MoryT Hcnojib30BaTbCH fljpyrne $H3HOJiorMnecKM οοβμθο THMbie KOMnJieKcoo6pa30BaTejiH, HanpHMep, uHTpaT EDTA, ΠΤΑ, naH-TOTeHaT. B na^ecTBe pacTBopHTeJiH Hcnojib3yioT miCTyio BO,iļy .iļjih ηηβθκ-Ι1ΗΟΗΗΗΧ IļeJieH, K KOTOpOH ^JIH yCTaH0BJI6HHH H30T0HHH flO6aBJIH10T- ch θΐηβ 0,5-10 γ/ji xjiopn£a HaTpun hjih cooTBeTCTByioiHHX Ben^ecTB,
KaK MaHHHT, COpČHT H T.fl. JIjih noJiyvemH npefiJiaraeMbix corjiacHO K3odpeTeHHionperiapa-tob Bce BcnoMoraTejibHbie BeujecTBa pacTBopniOT b ηθο^χο,π,ημομ KOJiH^ecTBe BOflbi, npHMeuiMBaioT EPO-npenapaT, κοτορΗΗ ,π,οϋΚθΗ HMGTb aKTHBHOCTb ΠρΜΜθρΗΟ 100000-200000 eflHHHlļ—μγ npoTenna, CTepHJībHo $MJibTpyiOT b cooTBeTCTByioiiļHe aMnyjibi, 3aMopa)KHBaK)T h οοτορο/ΚΗΟ JiHO$HJiH3HpyiOT πρκ ΗΜ3ΚΗΧ TeMnepaTypax. riojiyqeHHbie npenapaTbi ycTOfiqHBH b aTMOc$epe a30Ta b TeneHHe 2-χ λθτ npn 0°C m b Teveme I ro^a πρκ KOMHa-rHOH TOMnepaType. Πρκ ρβκοΗ-CTpywpOBaHHH c nOMOHļbB BOflH OHH paCTBOpHrOTCH 3a HBCKOJībKO ceKyHfl 6es πονοττηθημη h Tāme o(5pa30M,MoryT npHMO ββο,ιιητβοη nyTeM BHyTpKBeHHOū hjih bHyτρκμβπιιθ^ιηοh KH'BeKiļHH hjih nocjie pa3-tfaBJieHMH Η30Τ0ΗΗΗΘ0ΚΗΜΗ paCTBOpaMK (HanpHMep, paCTBOpOM XJIO-pHfla HaTpHH) BJIHBaTbCH. iIpon;eccy 3aMopasHBaHHH npH^aioT oco6oe 3HaneHHe. BcnoMora-TeJibHbie BeiqecTBa no po,ny κ KOJiHnecTBy BbičnpaīOTCH Tan, ητο<5h SBTeKTMnecKaH Tonna 3aMopajKMBaeMoro pacTBopa Haxo,iļHjiacb μθκ-ņy -50°C h -30°C. C πομο^μο ynpaBJiHeMOH κοΜΠΒατθροΜ nporpaMMbi onTHMH3aiTHH onpe,n,eJiHJiHCb cjie^mņie oriTHMajībHbie ycjioBMH ajih 3-Χ $a3 JIH0$HJIH3aiļHH:
BpeMH 3aM0paKHBaHMH: Ī2-I4 nacoB npn -40°G, ocHOBHan cyinKa: TeMnepaTypa paccojia +I0°C, flaBJieHHe 10”* MČap,
BpeMH 48-60 nacoB,
AonoJiHHTeJibHaH cymKa: TeMnepaTypa paccojia +20°C, flaBJieHHe 10”^ M(5ap, BpeMH 4-6 nācos. īlpn 3tom cymecTBeHHbiM HBJineTCH pacno3HaBaHHe c noMOirļbio M3MepMTejibHoro ycTpoHCTBa Δρ, a Tarace H3MepeHne 3JieKTpo-npoBOflHOGTH, Kor^a aaKOHtiHTCH ocHOBHan cyniKa, ητο6η jiho$hjīh-3HpyeMHiļ npo,iiyKT cjihihkom 6biCTpo ηθ HarpeBajiCH m hto6h H3(5e- 6 raTb ΟΤΤΒΚΒΒΗΗΗ 3aMOpomeHHOrO paCTBOpa H CBH3aHH0M c dthm no-TepH aKTHBHOCTH.
Mcnojib3yeMbie BcnoMoraTejibHbie Be^ecTBa BtidupaioTCH Tan, tiTo6bi ocyiiļecTBJiHJiocb o6pa30BaHne paBHOMepno οτργκτγρκροΒβΗ-ηογο Jino$MJiM3HpyeMoro 3aMep3mero TeJia h bo BpeMH JiH0$HJiH3a-ujm noJiynajicfl nopncTbin cnejieT (ocaflOK Ha $mibTpe), M3 koto-poro B03M0)KHa onTHMajībHaH cy()JiHMaiņīH Jibfla, npeacfle Bcero,TaK-κθ,κ KOHuy ochcbho$ cyiiiKn. .IļonoJiHtfTejibHafl cyniKa ocymecTBJiHeT-ch, KaK yKa3ano Bbiiue, tojibko npn +20°C b Tenemie 4-6 nācos. 3Ta ocropojKHaH o(5pa6oTKa ηβληθτοη BajKHoft, TaK KaK HHane npn-BOJļMT K ΠΟΤβρβ aKTMBHOCTH B CJiytiae CJIHIIIKOM JIH0$MJIH31ip0BāHH0-ro MaTepnaJia.
KaK npaBHJIO, TaKMM 06pa30M JIH0$MJIH3Mp0BaHHbie npoflyKTH ΗΜθίοτ coflepjKaHHe βο,π,η no K.$Mmepy npHMepHO 2-5¾. 3το ocTaTon-ηοθ coflepKaHHe βο,π,η 3ββηοητ ot po^a h KOJinnecTBa BcnoMoraTeJib-Hbix BemeCTB, κοτορΗθ HcnoJib3yioTCH b cooTBeTCTByioineM peiļenType.
BoflHbie pacTBopbi CTa6HJiH3KpoBaHHoro EPO mojkho TaKKe Henoc-peflCTBeHHO 3ajiHBaTb b aMnyjibi h de3 jino$MJiH3aiļMH b βη,π,θ γοτο-boh κ ynoTpe6jieHHio φορΜΗ ncnojib30BaTb. ΥοτοίίηΗΒΟΟΤΒ, OflHaKO, ČJiaroftapH 3TOMytno cpaBHeHHio c Jiwo$MJiH3aTOM, coKpamaeTCH npn-MepHo flo I ro^a npn 0°C η ηθοκολβκηχ MecniļeB npn KOMHaTHOž T6MnepaType.
Hn?KecJieflyioi]ļKe npuMepbi aojijkhh 6ojiee nodoto ποηοηητβ BbiffleonMcaHHoe:
ΠρΗΜθρ I
Cyxoe BerEļecTBO ajih ΗΗΈβκιρίΗ c 2000 ejpīHHij BpHTponoHSTHHa (cocTaB flJiH 35000 aMnyji). B CTepnjibHOM, CHa0®eHHOM MeniajiKoft , θμκοοτβιο IOOji ¥2 pe3epByapa c αβομηομ py6aiiiKon pacTBopniOT BcnoMoraTejibHbie Ben\ecTBa: MoneBHHa 700,0 r XJĪOpHfl ΗΒΤρΗΗ 70,0 r Tbhh 20 7,0 r $HrKflpO$OC$aT HaTpHH X I H^O 36,4 r ,IķiHaTpnMrH1iipo$oc$aT x 2 H^O 350,0 r Χ-πορη,π, Kajībi^HH x 2 H^O 6,4 r Γϋηπ,ΜΗ 105,0 r LV 10178 140.0 r 140.0 r 35.0 r 35.0 r 70.0 r flo 70,0 ji L - JieMIļHH L - H30JieMiņiH L - ΤρβΟΗΗΗ L- rjiyTaMHHOBaH KHCJiOTa
L - (^eHMJiajiaHHH BOfla flJIH ΜΗ'ΒβΚΕζΗΟΗΗΒΙΧ iļejien K 30 jī 3Τ0Γ0 BcnoMoraTeJibHoro pacTBopa ^oOaBJiniOT 214,3 mji cbipbeBOK 3arpy3KH 3pHTponon3THHa c THTpOM EFO 140000 θ,π/mji κ flOJiMBaroT flo KOHetiHoro ofoeMa 35 ji h nepeMeiiiMBaiOT. C noMOiiļbio ocTa^bHoro pacTBopa BcnoMoraTeJībHtix BenļecTB cnojiacKHBaioT cmc-TeMy $HJibTpaiņiH. PacTBop cocTaBa cT.epmībHO $HJibTpyK)T nepe3 MeMdpaHHHM $HJIbTp C paSMepOM nop 0,2 MKM. CTepHJIbHO npO$MiIb-TpoBaHHHfi pacTBop b acenTH^ecKMX ycjioBMHx 3ajīMBaK)T b ckjihhkh flJIH MH'beKIļHM eMKOCTbK) I MJI H CydJIMMaiļMOHHO BblCyiHMBaK)T B yCTa-ΗΟΒκβ fljifl JiH0$HJiH3aiņiH πρκ cjiejiyioinHx κρκτθρΗΗχ:
BpeMH 3aM0pa®HBaHHH: 12-14 nacoB πρη -40°C,
flonojiHKTeJibHaH cyniKa: T6MnepaTypa paceojia +20°C, ^aBJieme I0~^ M(5ap, BpeMH 4-6 nācos.
IloJiyqaK)T TaraiM 0(5pa30M od^eMucToe, c otkphthmh nopaMK, cy-xoe BeiDļecTBO ,π,ιιη ηηέθκρμμ, κοτοροθ CTaČMJībHo, no KpaftHeft Mepe, 2 rojļa b KOJioflMJībHMKe η I το,ς πρκ κομηβτηοη TeMnepaType η b τθηθηηθ ηθοκοηβκμχ nacoB pacTBopneTCH b 2 mji BOflH jpa HirbeK-η,ηοΗΗΗΧ iļeJieK <5e3 noMyTHeHHH κ ημπθηηημ nacTMp. ΠρκΜθρ 2
JlH0$HJIH3aT C 200 eflHHMIļaMH OpHTpOriOHSTHHa (cocTaB fljiH 35000 aMnyji).
3ρΗΤρ0Π0Η3ΤΗΗ 46,7 MJI = 7 M O eflHH
Xjiopnfl HaTpHH 100,0 r 10.0 r 155.0 r 500.0 r 10.0 r 1000,0 r
Tbhh 20 JĻirHflpo$oc$aT HaTpHH x I HgO 1H1HHaTpHfīrHlņpo$oc$aT x 2 HgO Xjiopnfl KajībtļHH x 2 H^O MoneBHHa δ 150.0 r 120.0 r 165.0 r flO 70,0 ji L- JieftiļKH L - ΤρθΟΗΜΗ
L - $eHHJiajiaHHH
Bo^a fljifl ηηί>θκι1ηοηηβιχ qejieft
BcnoMoraTeJibHHe BenjecTBa paCTBOpniOT b 70 ji BOflM fljin ηηέθκι];ηοηηηχ iļeJieM h 3aTeM pa3flejifnoT. Ha 2 nopiņiH no 35 ji. IlepBbie 35 ji CMemuBaiOT c ηθο^χο,π,ημβιμ κολιριθοτβομ EP0-6hojio-ranecKu aKTMBHoro BemecTBa. Βτορπβ 35 ji Hcnojib3yiOT flJiH cno-JiaCKHBaHHH CKCTeMbl $HJIbTpaiļHH. PaCTBOp COCTaBa CTepHJIbHO $HJĪb· TpyK)T nepe3 MeMČpaHHtift $hjibtp c pa3MepoM nop 0,2 mkm. CTepmib ho npo$HJibTpoBaHHHH pacTBop npn acenTHnecKHx ycJiOBMHx pa3Jin-BaiOT B CKJIHHKM ftJIH MHbeKIļHH eMKOCTbK) I MJI M JIHO$HJIH3HpyiOT ΠρΗ τθχ »e κρητβρκΗχ, KaK yKa3aH0 b npuMepe I. riojiynaiOT TaKMM 06-pa30M 6ejioro iļBeTa, nopucTbin, χοροιπο pacTBopHMHft b 2 mji BOflH JIH0$HJIM3aT, KOTOpbin Μ03ΚΘΤ XpaHHTbCH 063 (5oJIbUIHX ΠΟΤβρΒ aKTHB-HOCTH 2 rO,n,a B XOJIOAHJIbHHKe HJIH I TOfl npn KOMHaTHOH TeMnepa-Type. ΠρηΜθρ 3
JlH0$HJIH3aT C 1000 GflHHKIļaMH 3piITp0n0H3THHa (cocTaB flJiH 35000 aMnyji) 3ρητροποΗ3ΤΗΗ 233,33 ΧΐΪΟρΗ,Π, HaTpHH 100,0 Tbhh 20 12,0 1iļHrH(3]pO$OC$aT HaTpHH X HgO 140,0 ,HHHaTpHHrHIiilpo$oc$aT x 2 H^O 450,0 XjiopH,n KajībiļHH 2 H^O 10,0 ; MoneBHHa 700,0 PjIHIļHH 1050,0 L - JieMLJMH 92,0 L - rjiyTaMHHOBaH KHCJiOTa 103,0 L - $eHHJiajiaHHH 115,5 Bojļa ^jih HH'beKiļHOHHbDc iļejiež j\o 70,0 . 35 Μ o e^HH.
BcnoMoraTejibHbie BeiņecTBa paCTBOpniOT b 70 ji βο,ιι,η fljin HHbeKiļHOHHbK iļeJieH h 3aTeM pas^eJiaiOT Ha 2 nopiļnn no 35 ji. riepBbie 35 ji CMemHBaioT c ηθο6χο,πημημ KOJinnecTBOM ΕΡ0-6μο;ιογη- LV 10178 necKH aKTHBHoro BenjecTBa. Βτορκθ 35 ji Hcnojib3yioT jļhh cnojiac-KMBaHMH CHCTeMbl flflR $HJIbTpai;HH. PaCTBOp COCTaBa CTepHJIbHO $HJibTpyiOT xiepe3 MeMČpaHHMH $HJibTp c pa3MepoM nop 0,2 mkm. CTepHJIbHO ĪIpO$HJIbTpOBaHHHtt paCTBOp πρπ ΒΟΘΠΤΗΗβΟΚΗΧ yCJIO-ΒΗΗΧ 3aJIHBaiOT B CKJIHHKH flJIH ΗΗΊΒΘΚΙ1ΗΜ eMKOCTbK) ΠΟ I MJI H JIHO-$HJIH3Hpyi0T πρπ ΤβΧ Ηθ ΚρΗΤβρΗΗΧ, KaK OnUCaHO B npHMepe I. īloJīynaioT TaKHM o6pa30M Čejioro īļBeTa, nopncTbifi, χοροιπο pacT-BOpMMblH B 2 MJI BOflbl JIH0$HJIH3aT, KOTOpblH M0IK6T XpaHHTbCH 2 roflā b xojio1nlHJibHHKe hjih I ΓΟβ πρκ κομηβτηοη TeMnepaType, βθ3 (50JībIDHX nOTepb aKTHBHOCTH. IIpHMep 4
JlH0$HJĪH3aT C 500 eflHHHlļaMH 9pMTponOH3THHa (cocTaB flJiH 35000 aMiiyji).
3ρΜΤρ0Π0Η3ΤΜΗ XjIOpHA HaTpHfl Tbhh 20 βΗΓΜβρθφθΟ(|&Τ HaTpHH X HgO 1I3IHHaTpHKrHppo$oc$aT x 2 HgO XjiopHfl KajībiļHH x 2 H^O MoHeBHHa L - JieHIļHH L - rjiyTaMHHOBan KHCJiOTa L - $eHHJiajiaHHH Bopļa fljiH HH'BeKiļHOHHbK iļeJieM 116,67 mji = 17,5 Μ ο θ,π,κη. 70,0 r 7,0 r 38,5 r 490.0 r 5,6 r 840.0 r 92,4 r 105.0 r 119.0 r ,π,ο 70,0 ji
BcnoMoraTejibHbie Be^ecTBa pacTBopnioT b 70 ji βο,π,η jļjih HHrbeKUļHOHHbix ijejiefi h 3aT6M pa3,D;ejiHiOT Ha 2 nopiļHH no 35 ji. īlepBbie 35 ji CMeniHBaioT c Ηθοδχο,π,ΗΜΗΜ KOJinnecTBOM ΕΡ0-6ηοιιογη-necKH aKTHBHoro BenļecTBa. Βτορκβ 35 ji HcnoJib3yK)T ajih cnojiac-KMBaHHfl CHCTeMbI ftJIH <ļ>HJIbTpaii;HH. PaCTBOp COCTaBa CTepHJIbHO $HJIb-TpyiOT nepe3 MeMČpaHHbift $hjibtp c pa3MepoM nop 0,2 mkm. CTepHJIbHO npo$HJibTpoBaHHbiH pacTBop pa3JiHBai0T πρκ acenTKiiecKHX ycJiOBHnx b CKJIHHKH flJIH HHT>eKIļHH eMKOCTbK) ΠΟ I MJI H JIHO$HJIH3HpyiOT ΠρΗ ΤβΧ m KpHTepHHx, KaK yKa3aHO b npHMepe I. riojiynaiOT TaKHM o(5pa30M 6ejioro i^BeTa, nopHCTHft, χοροιπο pacTBOpHMHH b 2 mji BOflbi jiho$k-JiH3aT, KOTOpbift Μοκβτ xpaHHTbCH 6e3 <5ojibniHX noTepb aKTHBHOCTH ΙΟ 2 ro^a Β XOJIOflMJIbHHKe MJIM I rOfl, npw KOMHaTHOM T6MnepaType. ΠρΜΜθρ 5
JlH0$HJIH3aT C 750 e/ļMHHIļaMK 3pHTponOH3TMHa (cocTaB ,π,ιγη 35000 aMnyJi). 3ρητρ0Π0Μ3ΤΗΗ 175,0 mji XjIOpH,H HaTpHH 100,0 r Tbhh 20 12,0 r ,IķīrMii^^oc$aT HaTpHH x HgO 140,0 r ,HnHaTpMi!rH1iij^oc$aT x 2 H^O 450,0 r XjIOpHft KaJIblļHH x 2 H^O 10,0 r TjIHIļHH 1250,0 r L - H30JieiilļMH 98,0 r L - rjiyTaMHH0Bafl KHCJioTa 130,0 r L - φθΗΐυΐΕ;ΐΒΗίΙΗ 145,0 r Bofla flJIH ΗΗΈβΚΙξΗΟΗΗΗΧ iļeJieft flo 70,0 ji = 26,25 Μ 0 ββΜΗ.
BcnoMoraTejibHHe BemecTBa pacTBopniOT b 70 ji BOflH ,π,^ιη ΜΗΒβκυ,ΜΟΗΡίΗχ iļeJieM h 3aTeM pasflejiHiūT Ha 2 nopiņra no 35 ji.
IlepBBie 35 ji CMGinuBaiOT c ηθο(5χοαημβιμ KOJinnecTBOM EPO-tfuojiora-ηβοκη aKTHBHoro Be^ecTBa. ΒτορΗβ 35 ji Hcnojib3yiOT jļjih cnojiac-KHBaHKH CHCTeMH flJIH $HJIbTpaiņiH. PaCTBOp COCTaBa CTepHJIbHO $HJIb-TpyioT nepe3 MeMdpaHHtiH φωΐΒτρ c pa3MepoM nop 0,2 mkm. CTepHJIbHO πpoφHJIbτpoBaHHL·Iκ pacTBop pa3JiHBaiOT npn acenTnnecKHx ycjiOBHHX b CKJIHHKH £JIH HHBeKiņift ΘΜΚΟΟΤΒΒ ΠΟ I MJĪ H JĪHO$HJIH3HpyiOT πρη ΤΘΧ »e κρητθρΗΗχ, KaK yKa3aH0 b npHMepe I. rioJiynaiOT TaKHM o6pa30M dejioro iļBeTa, nopHCTHH, χοροιπο pacTBopnMHn b 2 mji bo^h jiho$h~ JiH3aT, KOTopuii μοκθτ xpaHHTbCH 6e3 6ojibmnx noTepb 2 ro^a b xo-Jio,n,HJībHHKe hjih I ΓΟβ npn KOMHaTHOH TeMnepaType. ΠρηΜβρ 6 JļjIH ΤΟΓΟ, tļTOdbl HCnHTaTb θφφθΚΤΗΒΗΟΟΤΒ (aKTHBHOCTb) pa3- jinnHbDc CTadHJiH3aTopoB, cTaHflapTH^ petienTypy c 1000 efl. EPO/mji, KOTopan οο,π,θρτκκτ b KanecTBe οοηοβηογο CTa(5HJiK3aTOpa MoneBKHy, CMeniHBaiOT co CMecbio nojiKBHHMJimīppojiHflOHa c 6θ:ικομ, οοοτβθτοτ-ΒΘΗΗΟ, pa3JinnHbIMH aMHHOKHCJIOTaMH M npOflyKTbI ΛΗθφΗΛΗ3Ηρ^Τ0Τ. Pe3yjibTaTbi npeflCTaBJieHH b Tadjmije I. LV 10178 CTačmībHOCTb EPO nocjie 6 He^ejib xpaneHHH jih οφη JM3aTa npn 35°C, οοοτβθτοτβθηηο , 0°C, b τθοτθ Ha ceJie3eHKe mmum corJiacHO μθτο,π,ηκθ G.Kryp£aI b Exp. Hemrol .II, 649-660(1983), onpe^e- JIH6TCH cJie^roiEipiM o6pa30M:
CaMKaivi D-C^Pļ - Mbinien βθοομ, npMMepHO, no 20 r (UeHTpajībHbift Mhcthtjtt fijin noKynaTeJieii ποαοπητηηχ κηβοτηηχ, raHHOBep) b flBā nocjieAOBaTeJibHbix ,π,ηη bbo,e,hjim nyTeM ΗΗΈθκίζΜΗ KHTpanepKTO-HeajībHO 60 μγ/κγ $eHHJirH^pa3HHrH^poxjiopHfla. CnycTH cJieflyiDipe 3 ,π,ηη M3BJieKajm ceJie3eHKy, κπθτκη οθπθ3θηκμ cycneHflHpoBajiH b b CTepHJībHoK Ko/??pIett - cpe^e (MOfl,n$KiļnpoBaHHaH Ea^īe cpe,n,a A^fiecco + 584,0 μγ) ji L - rjiyTaMMHa + 0,1 MMOJib/ji 2-MepKan-TOBTaHOjia + 20% sapoflbimeBOK τθπηηβθη οπίΒοροτκη) h paedaBJiHJiM ρ,ο 4x10^ HflpocoflepjKainMx κπθτοκ/μπ. CycneH3Hio, κ κοτοροχ npem-fle Ao6aBJiflioT τθοτ-βθπ1ΘΟτβο, οοοτβθτοτβθηηο, EPO-CTaH^apT, CMOTpH ΠΟ 06CT0HTeJIbCTBaM, B ΠρΚΓΟβΗΒΐΧ ΚΟΗΒζβΗΤρΗΗ,ΗΗΧ, paCTBO-peHHbie b 3SA - 6y$epe, pacnpeflejinioT Ha πηβοτηηκβχ ,π,ηη ΜΗκρο-THTpa (0,2 MJi/yrjiydJieHze). Ποοηθ HHKy6ai#ra (22 naga, 37°C, B03^yx + 15% CO^) Ha yrJiy6jieHne jļodaBJiHioT 20 mkji ^Η-μθτηη-TMMHflHHOsoro pacTBopa c I ju.01 h CHOBa HHKy(5HpyiOT 2 naca npn 37°C. Ποοηθ θτογο co^epjKMMoe πθρθβο,π,ητ c noMonļbio κηθτοηηογο Parvt\sfer\s· h npoMbiBaiOT ,n,McrajrapoBaHHOM BOjļOH. Co^epjKaHHe ^-THMHflMHa Onpe^eHHĪOT C ĪIOMOIIļbKI J3 -Ci;HHTIUIJIHIļHOHHOrO ΟΗΘΤ-HHKa h oijeHHBaiOT no OTHomeHMK) κ CTaHflapTHHM npenapaTaM. B KanecTBe pačonero CTaH^apTa wenoJib3yK:T "P009-EP0-OTaH-flapT” PiHCTHTyTa Γθηθτηκη, ΚθΜ(5ρκ,π,?κ, MaccaqyceTC, ClILA, κοτορυϋ coflep?KHT 112 θα.ΕΡΟ(μλ) h 503 μγ npoTeHHa (mji) ypaBHeHHHH no ΟΤΗΟΠΙΘΗΗΚ) κ EPO-CTaHflapTy who International Referense Prepara tion of Erytropoietin, Human, Urinary for Bioassay /2 no I.R, P., established 1571/. CTaHflapTHbie KOHiļeHTpaiņiM Haxo,n,HTCH b oČnacTH 10—100 mv'/usi.
McnbīTbīBaionļnecH Ha ΕΡΟ-βκτηβηοοτβ JīH0$HJiH3aTH CHanajia, Ha aMnyjiy, paCTBopHJiH b 2 mji Βο,π,υ ,d,jih μηβθκη;ηοηηβιχ ι^θηθη, ocymecT-bjihjih ^ajībHeiimMe pa36aBJieHHH - TaroKe, kbk b cjiynae pačonero CTaHflapTa^- c ποΜΟΐςΜ) B5A - dy$epa (6,75 r NaCI, 1,95 r CaCI2 x x 2 H20, 1,00 γ B5A ο(5μηηηΜ chbopotohhhh ajib6yMHH φζρΜΗ( CaL-biochem ) BO^a jļjih ηηέ>θκιρϊοηηηχ ι^θηθμ ,π,ο I ji) . 12 Ο °H-MeTHJĪ-TMMH1DlMH y^eJībHaH aKTHBHOCTb: 2 C /MOJIJIb nOJiy^aJIH ot New England Nuclear. ΠρΗΜθρ 7
TaKHM Hte o(5pa30M, nan η b npHMepe 6, ηθοκολβκο M3MeHeHHyio niTaMM/peiļenTypy CMeniHBajiH c μο^θβμηομ h pa3JiM^Hb!MM θ,μμηοκηολο-TaMH, ΟΟΟΤΒβΤΟΤΒβΗΗΟ, CM6CHMK. £jlH CpaBHeHHH MCCJieflOBaJIH flBe coflepstaiņie MaHHHT peuļenTypH, κοτορΗθ οοοτβθτοτε^ποτ eBponeūc-KOMy naTeHTy 178665. Pe3yjibTaTbi npe^CTaBJienbi b Tatfjnme 2. LV 10178
Tačijmiļa I
CocTaB Mr/a.Mnyjiy I 819592 G 819893 H 6 819894 I a(5 819985 K 3ρΗΤρ0Π0Η3ΤΜΗ B ββ. 1000 1000 1000 1000 MoneBHHa 10,0 10,0 10,0 10,0 XjIOpHfl HaTpHH 9,0 4,0 9,0 1,0 Tbhh 20 0,1 0 %# 1—1 o 1—1 1—1 0 IlwrMirpo$oc$aT HaTpMH X Η<?0 0,55 0,55 0,55 0,55 JļHHaTpHKrHflPO- $oc$aT x 2 H^O 5,0 5,0 5,0 5,0 CaCĪ2 x 2 H20 0,08 0,08 0,08 0,08 KojuiHflOH 12 PF 5,0 - 5,0 - rajia$yHjļHH 1,0 0 t—1 - - rJIHIļHH - 15,0 - 15,0 L - jieMiļHH - - 2,0 2,0 L - H30JieftlļHH - - 2,0 2,0 L - TpeOHHH - - 0,5 0,5 L - rJiyTaKHHOBan KHCJiOTa - - 0,5 0,5 L - $eHHJiajiaHHH - - 1,0 1,0 BO.D.a B MJĪ βο 1,0 βο 1,0 βθ 1,0 βο 1,0 CTa^HJIBHOCTb npw 25 °C 493 869 934 1128 CTadHflbHOCTb ripu 0DC 985 III4 IĪĪ4 1205
TadJiMD,a LO CO 00 o o 1—1 LO o o 02 LO •v rv — rv rv 1 o 1 1 CO ο 02 1—1 O CD LO O 1—1 rv σι LO CO l-H o o l—l LO O O CM ζ> to ·> rv *· r» rv 1 1 LO 1 CO ο 02 1—1 o O LO o l-H rv σ> o LO co CM l—l ο o ι—i LO O o CO LO rv rv r% rv rv 1 O 1 1 ο 02 l-H O O LO o l—l l—l σ> LO co CM o o 1—1 LO o o CO LO LO rv *v rv rv rv 1 1 LO rv 1 ο 02 t—1 o o LO o l—l hH σ> o to co CM O 1—1 LO O o co LO «s «V rv rv rv 1 o 1 1 rv ο φ 02 1—1 O o LO o l—l l-H O LO co 02 O 1—1 LO O o co CO LO rv rv rv rv * 1 1 LO 1 rv ο 02 1—1 O o lo o l—l 1—1 0¾ LO co CM 02 O O 1—1 LO o o co LO rv rv rv rv rv 1 o 1 rv t Ο CX2 HH O o LO o l-H l—l σ> LO co CV o o 1—1 LO O o co 1—1 LO ·* r> rv rv rv 1 1 LO rv 1 ο CM 1—1 o O LO O l-H l—l σ> O LO CO 02 O 1—1 LO O o CO ο LO r» rv rv rv 1 o 1 1 rv ο CM I—1 o O LO o l—l t-H σ> σ> O LO co 02 O 1—1 LO o o CO σ> LO rv •N rv rv rv 1 1 LO 1 rv CO CM 1—1 o O LO o l-H l-H C0 02 LO 00 02 O O h-1 LO o o CO σ> LO #v «0 rv rv rv i o 1 rv 1 00 02 1—1 o O LO o l-H hH Γ- LO 00 CM O O (—i LO O o co σ> LO «'» ·* rv rv rv 1 1 LO rv 1 00 CM M o o LO o l—l l—l Ο LO co 02 O O l-H LO O o CO σ> LO rv rv «V rv 1 o 1 1 rv 00 CM t-H O o LO o l-H 1—1 LO co 02 ιο o O 1—1 LO o o CO σ> to *> *- rv rv rv 1 1 LO 1 rv 00 CM l—l O o LO o l—l l-H (=2 tu 1 o « S cd E Eh O CM s X \ Ch S Pv cd >θ< pp ΕΓ ►Q & S co · o S02 t=2 X Λ 5£ >>t=C cd o E cd S t=2 CD m P*<D £ O 5S X w cd £O fe; Ch ct O o s X >£ 2 O m cd m 02 oo PviH t=C s X ω CO 0* cd co s t=C 02 E-* cd so s CQ S 1=30 s Λ e-< Γ Py X cd>0< Py CM X ω ΕΓ o C o ΟΟ O J5 X o OK £ £ s 1 1—1 1 ο o o *=2 X CQ E-t S cd 1=¾¾ āS K XCM cd s o r—-t 1=3 Ch 1—3i-h a npoAOjraceHHe TatfjiHiļbi 2 ΙΩ co 02 cO o o co o o r* 1 *s 1 * 1 « 1—1 1—1 cr> I—1 t—1 1—1 1—1 cv 02 LO 2> 02 cO O IO ω o r* 1 ψ\ 1 f 1 1 o co CJ> t—f t-i 1—1 C\2 1—1 ļ> to cO cO O 00 1—1 o l ·* e» 1 l LO LO σ> σ> 1—t t—i 1—1 CV2 02 2> LO UO cO O t—l o O 1 *> r» 1 1 Γ WS cv 02 σ> 1—( 1—1 t—l 02 02 2> ΙΩ cO O LO 2> o 1 •N 1 1 ΙΟ #» O c0 σ> 1—1 1—1 1—1 CN2 1—1 2> LO co 'Ci4 cO O CT» O o 1 r» r» 1 1 02 •s C\2 CO σ> t—t 1—1 1—1 C\2 02 02 02 Γ- O cO O o 1 1 r> 1 1 ·> C\2 co σ> 1—1 1—1 l—l C\2 02 t—t 02 ^d4 !> o cO 02 o r> 1 1 1 1 C\2 CO (7» i—l 1—1 1—1 C\2 02 O 02 'd4 2> O σ> O 1 1 #s 1 1 02 co CT> 1—1 1—1 t—l 02 02 cr> 02 'd4 2> O O co σ> ·> 1 1 ** 1 1 O- o co t—1 1—1 1—1 1—1 02 £> uo co Kt4 ž> o o 02 cr> 1 1 #% •t 1 0\ C0 'Cj4 co 1—1 1—1 1—1 (—1 02 02 2> ^4 z> 'ci4 o- o O CO CJ1 1 ·* 1 I 1 *> LO O 00 t—1 1—1 1—1 t—l 02 cO Z> 'Ci4 ’nT o- o o LO CO σ> 1 1 ·» l ·> CO o co 1—1 1—1 t—1 i—i t—l 02 2> ^i4 o 02 ίο 'NĪ4 0- O ·> cO 00 σ> 1 «V 1 ·» •N 1 1—1 1—1 1—1 00 1—1 1—< H 3S te! s cd X o tr m K 02 « o X o oc 0) X cd 02 £ Λ Λ X s 1=5 *T* K 02 X Eh e K s cd s s O o K cd 1=5 K X X O o o s s te! X X <D >>cd X o ^t4 «ej4 t=5 O Λ X P/ ^ Eh ω Pv o O t=Ct=C t=3 t=5 t< E-i o O cd Ph Ph S S Γ3 02 02 cd t=5 ΌΟ VD C o 1 1 o Λ S 1 1 «=CS o «o fr<io cdO to i-A t-1 w 1-1 Z Z ĪQ cq 002 oo LV 10178 02 npoflOJDKeHHe TadJiHLļbi LV 10178 Ο C0 LO ο Ο Ο ο ο Γ ιο Ρ1 r% #> ο 1 1 1 1 1 ΙΟ 02 Ο Ο ο ο C0 cO ο C0 ο I—I ο ο ο Γ LO ο 1 ο 1 1 1 ιο 02 Ο ο ΙΟ ο 02 1—ι ο 00 02 ο Ο t—1 ο ο ο co ΙΟ «S ψ\ #Ν I ο 1 1 1 1 σ> 02 1—1 ο ο ο ο (—1 02 ο C0 ο ο 1—I ο ο ο l—l ΙΟ CS 0S •S ι 1 ο ι 1 1 σ> 02 Η-1 Ο ο ο ο 1—1 ο C0 1—1 ο Ο 1—1 ο ο ο 1—1 ιο *» *Ν •V ** 1 ο ο ΙΟ σ> 02 1—1 Ο ο ο ο (—1 1—1 02 1 " ο ο ο 00 02 02 Ο Ο t—I ο ο ο 00 * 1—1 Ο «S «*> #s 0\ «V 1 ο 1 1 ι—ι σ> 02 hH Ο ο ο ο 1—1 I—1 σ> ο C0 02 Ο ο 1—1 ο ο ο 00 02 ο Ο #* «V C* 1 1 ο •S 1 σ> 02 Η-1 Ο ο ο ο n 1—1 ι—ι \ cd P w 2 co · >>t=C m p*a> p ffl crf ffl cd co P 2> O OO P S Pv P cd P P cd >θ< o o >eo I o O 02 g* S02 P 5S X I JS Q) P O CO s
επ P C O
θ 6S
(=C S Pv op X ocv Psra E-t P s ΡΓ pp cd «o t=C 02 sp Pv OC\2¢=¾¾ t=ī>e< x x o 02 s Ρ£Ρ PvP l=t P cd S X cd>0< P P O s cd s o ps P P cd
cd P •r^3<DPO
Pscrsp
P Λ S P ΗΌ <s 2 ω POo l H
I P S
Ps P0Q> Pv ĒH1 t-, (—11—i h4 īzT t~ļ 02 LV 10178 npoflOJDKeHHe Tadjunļbi 10 o CO r~ ( 1 1 1 Γ- D~ LO t—1 C7> t—1 cO o s 02 Γ I 1 1 1 τ> ΙΟ 1—1 t—( 1—1 02 o o ΙΟ co I 1 n 1 w» C\2 Φ cr> 1—1 1—1 1—1 02 o LO CO 1—I I 1 1-1 1 r~ 1—1 Qī HH Η-1 02 I—I LO o o CO S I—I «s #> 1 1 »> LO σ> o 1—1 1—1 C\2 02 LO o o o O ι—i I ·> 1—1 1 *> 1 σ> 1—i 1—1 C\2 LO σ> co o 1—1 P- o I r» 1 1 «s o σ> σ> t—1 1—1 1—1 1—1 cd X o « o
02 o 3 02 | 1 o X cd cc tfl ec Λ Λ s 3 C\2 3 P· s cd s X S R o O cd t=i X X S o O EH s s « w 3 5¾ >iCd X P. o t; P Λ Λ »=s e· ω P# Ph O t=C E·* P. o O cd 02 Ph S s s 3 k cd s ΌΟ \0 C 1 o 1 1 C\i pcpt a£> cdO O 1 S tA Λ cd cd O w Ε-ΊΟ E-O 1-1 X p3 5¾ 525 CQ ω OC\2 OO LV 10178 18
ΦΟΡΜΥΜ M30EPETEHHH 1. Cnocod noJiy^eHHH οοβμθοτημηχ, ycToitoiBbix πρκ xpaHeHHH npenapaTOB ĪiejiOBe^ecKoro npoTenHa, coflep?KainHX ^eJioBe^ecKHii προτβΗΗ, $H3HOJiorHtieeKH coBMecTHMHē 6y$epbi, a TaKJKe,npn Heod-χο,π,ημοοτη,K0MnJieKC006pa30BaTeJiM, ycTaHaBjihBaiomHe h3otohhk> cpe^cTBa, xjiopHfl KajībiļHH h ,iy?yrjie, odtmHue ,ε,ιιη κη'βθκιριοηηηχ ijejiefi Be^ecTBa, OTJiH^aiDiiļHiicfl τθμ, tīto CHaiiajia ΓΟΤΟΒΗΤ paCTBOp 5-50 Mr/jl ΜΟ^ΘΒΗΗΗ, 1,50 r/jl aMHHOKHCJIOTH H 0,05-5 γ/ji ηθηοηηογο CMatjHBaTeJifl, κ 3T0My pacTBopy flodaBJiniOT odbRHHe BcnoMoraTeJibHbie BemecTBa m 3aTeM npuMeinuBatoT TieJīOBe-^eCKHft ΠρΟΤΘΗΗ. 2. CnOCO(5 ΠΟΠ.Ι, OTJIH^aiOIIļHHCfl TOM, TĪTO aMHHOKHCJiOTa npe^CTaBJiHeT codoīi CMecb, KOTopan co^epscuT tjih-iļHH, L- ajiaHHH, L- apniHHH, L- JiefiiļHH, L- η30λθηι1ηη, I - 2 - $6HHJiajiaHHH, L- rjiyTaMHHOByio KHcjiOTy h/hjih L·- τρβ- OHHH. 3. Cnocod no n.2, OTJiHTiaioiHHftCfl τθμ, tīto b KatiecTBe CMa^HBaTeJiH ncnojib3yiOT nojiH3THJieHCopdnTaHJiaypaT. 4. Cnocod no JiiodoMy H3 n.n.I-3, ouioaioiiļHiicfl τθμ, ητο npenapaT ηβχο,ε,ητοη b jmo$HJiH3npoBaHHOH φορΜθ. 5. Cnocod no jnodoMy H3 n.n.I-4, OTJiHuaioiiļHiicii τθμ, ητο npenapaT ηβχο,π,ητοη b κκ,κ,κοΚ, cnocodHoK BnpHCKHBaTbCH, φορΜθ. 6. Cnocod no jnodoMy H3 n.n.I-5, OTJiHTiaioinHiiCfl τθμ, tīto Ha e,iļHHHLiy A03H ηιτβθκι^ηη 1-5 mji co.n.epmaTCfl 100--1000000 eflHHHiļ TiejiOBetiecKoro npoTenHa. 19 7. Cnocod nojiyyeHHH npenapaTa no n.n.I-6, OTJinnaio-m H β C fl ΤΘΜ, tITO tieJIOBetieCKHM ΠρΟΤβΚΗΟΜ HBJIHeTCH θρητρο-Π0Η3ΤΗΗ. 8. Cnocod nojiyneHHH npenapaTa ^eJiOBe^ecKoro npoTenHa no n.7, OTJiH^aroiiļHiicfl τθμ, ητο Ha eflHHra^ β03Η HHbeKiļHH 1-5 mji co^epmaTCH 100-20000 eflHHHn epHTpononeTHHa. 9. Cnoco6 nojiy^eHHH npenapaTa nejioBenecKoro npoTeHHa no n.7, ouiH^aiopiicfl τθμ, ητο CHanajia Bce Bcno-MoraTejibHbie BenļecTBa pacTBopfliOT b βο,π,θ, flOČaBJiniOT θρητροποη-3THH, CMecb CTepnJibHO $HJibTpyioT b aMnyjiH η οοτοροκΗΟ πρη τθμ-nepaType Hirace - 20° jmo$HJM3Mpyi0T. 10. Cnocoč noJiyneHHH npenapaTa neJioBenecKoro npoTenHa no n.7, OTJinnaio^HficH τεΜ, ητο CHanajia Bce Bcno-MoraTeJibHbie BemecTBa pacTBopnioT b βο,ιι,θ, flO(5aBJiHiOT epHTponon-3thh h CMecbK» 3anojiHHK)T aMnyjiH.
Claims (10)
- LV 10178 Patentformulas punkti 1. fizioloģiski savienojamu, glabājot stabilu cilvēka olbaltumvielu preparātu, kuri satur: cilvēka olbaltumvielas; fizioloģiski savienojamus buferus; ja nepieciešams, arī kompleksveidotājus; izotoniska osmotiskā spiediena nodrošinātājus; kalcija hlorīdu un citas injicējamos preparātos parastas vielas, iegūšanai, kas atšķiras ar to,, ka vispirms pagatavo šķīdumu, kas satur 5-50 mg/1 urīnvielas, 1-50 g/1 aminoskābes un 0,05-5 g/1 nejonogēna slapinātajā, un iegūtajam šķīdumam piejauc cilvēka olbaltumvielu.
- 2. Paņēmiens pēc punkta 1, kas atšķiras ar to, ka par aminoskābi izmanto maisījumu, kas sastāv no glicīna, L-alanīna, L-ar-ginīna, L-leicīna, L-izoleicīna, L-2-fenilalanīna, L-glutamīnskābes un/vai L-treonīna.
- 3. Paņēmiens pec punkta 2, kas atšķiras ar to, ka par slapinātāju izmanto polietilēnsorbitānlaurātu.
- 4. Pec je^kura no punktiem 1-3, kas atšķiras ar to, ka preparāts ir liofilizētā formā.
- 5. ' Paņēmiens pēc jebkura no punktiem 1-4, kas atšķiras ar to, ka preparāts ir šķidrā injicējamā formā.
- 6. Paņēmiens pēc jebkura no punktiem 1-5, kas atšķiras ar to, ka 1-5 ml liela injekcijas deva satur 100-1000000 vienību cilvēka olbaltumvielas.
- 7. Paņēmiens pēc jebkura no punktiem 1-6, kas atšķiras ar to, ka cilvēka olbaltumviela ir eritropoetīns.
- 8. cilvēka olbaltumvielas preparāta iegūšanai pēc punkta 7, kas atšķiras ar to, ka 1-5 ml liela injekcijas deva satur 100-20000 vienību eritropoetīna.
- 9. Paņēmiens cilvēka olbaltumvielas preparāta iegūšanai pēc punkta 7, kas atšķiras ar to, ka vispirms ūdenī izšķīdina visas palīgvielas, tad pievieno eritropoetīnu, maisījumu sterili filtrē ampulās un uzmanīgi liofilizē pie temperatūras zem -20 °C.
- 10. PēSl!ūi®5S cilvēka olbaltumvielas preparāta iegūšanai pēc punkta 7, kas atšķiras ar to, ka vispirms, ūdenī izšķīdina visas palīgvielas, tad pievieno eriropoetīnu un maisījumu iepilda ampulās.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873729863 DE3729863A1 (de) | 1987-09-05 | 1987-09-05 | Stabilisierte erythropoietin-lyophilisate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10178A LV10178A (lv) | 1994-10-20 |
| LV10178B true LV10178B (en) | 1995-04-20 |
Family
ID=6335375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-93-470A LV10178B (en) | 1987-09-05 | 1993-06-02 | Method of preparation of physiologically acceptable, stable in storage protein composition |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US4992419A (lv) |
| EP (1) | EP0306824B1 (lv) |
| JP (1) | JPH0780782B2 (lv) |
| KR (1) | KR960009929B1 (lv) |
| CN (1) | CN1027224C (lv) |
| AT (1) | ATE77556T1 (lv) |
| AU (1) | AU610636B2 (lv) |
| CA (1) | CA1330301C (lv) |
| CS (1) | CS274681B2 (lv) |
| DD (1) | DD273004A5 (lv) |
| DE (2) | DE3729863A1 (lv) |
| DK (1) | DK174811B1 (lv) |
| ES (1) | ES2051806T3 (lv) |
| FI (1) | FI93517C (lv) |
| GR (1) | GR3005454T3 (lv) |
| HK (1) | HK89495A (lv) |
| HU (1) | HU202761B (lv) |
| IE (1) | IE60310B1 (lv) |
| IL (1) | IL87628A (lv) |
| LV (1) | LV10178B (lv) |
| MX (1) | MX12880A (lv) |
| NO (1) | NO178687C (lv) |
| NZ (1) | NZ225975A (lv) |
| PH (1) | PH25618A (lv) |
| PL (1) | PL157944B1 (lv) |
| PT (1) | PT88417B (lv) |
| RU (2) | RU2043118C1 (lv) |
| UA (2) | UA26855C2 (lv) |
| ZA (1) | ZA886528B (lv) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
| DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| DE4014654A1 (de) * | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
| DE4126984A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US20030035845A1 (en) * | 1992-06-11 | 2003-02-20 | Zale Stephen E. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) * | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| EP0582933A1 (de) * | 1992-08-11 | 1994-02-16 | F. Hoffmann-La Roche Ag | Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren |
| DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| JP2747979B2 (ja) * | 1994-08-19 | 1998-05-06 | 雪印乳業株式会社 | ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬 |
| IL116085A (en) * | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
| ZA966075B (en) * | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| CA2230494A1 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
| DE19539574A1 (de) * | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
| US20030138402A1 (en) * | 1995-12-25 | 2003-07-24 | Otsuka Pharmaceutical Co., Ltd. | Dry compositions |
| US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| TW518219B (en) * | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| KR20000069664A (ko) * | 1996-12-24 | 2000-11-25 | 아스트루 마이클 제이 | 안정한 액체 인터페론 제제 |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| DE19716154A1 (de) * | 1997-04-18 | 1998-10-22 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren |
| US6548296B1 (en) * | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
| US6391633B1 (en) * | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
| AR019025A1 (es) | 1998-04-09 | 2001-12-26 | Roche Diagnostics Gmbh | Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado |
| EP0965349A1 (de) * | 1998-06-18 | 1999-12-22 | Roche Diagnostics GmbH | Verwendung von Erythropoietin zur Behandlung von Hämochromatosen |
| JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| CA2369444C (en) * | 1999-04-09 | 2009-08-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| AU6875900A (en) | 1999-09-08 | 2001-04-10 | Chugai Seiyaku Kabushiki Kaisha | Protein solution preparation and method of stabilizing the same |
| EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
| AU2005225151B2 (en) * | 2000-05-15 | 2008-05-29 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
| JP5485489B2 (ja) * | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
| DE10149030A1 (de) | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| SI21257A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
| EP1641486B1 (en) * | 2003-06-10 | 2012-04-18 | LG Life Sciences Ltd. | Stable, aqueous solution of human erythropoietin, not containing serum albumin |
| FR2857267B1 (fr) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
| KR100560697B1 (ko) * | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | 알부민을 함유하지 않는 에리스로포이에틴 제제 |
| CN1897959A (zh) * | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
| US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| EP1537876A1 (en) * | 2003-12-01 | 2005-06-08 | BioGeneriX AG | Erythropoietin solution formulation |
| DE102004011663B4 (de) * | 2004-03-10 | 2006-04-27 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
| US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
| DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
| HUE049023T2 (hu) * | 2008-08-15 | 2020-08-28 | Ironwood Pharmaceuticals Inc | Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények |
| WO2011017502A2 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Linaclotide-containing formulations for oral administration |
| HUE034190T2 (en) * | 2009-11-03 | 2018-01-29 | Ironwood Pharmaceuticals Inc | Linaclitaxel for the treatment of chronic constipation |
| WO2011090306A2 (en) * | 2010-01-19 | 2011-07-28 | Hanmi Holdings Co., Ltd | Liquid formulations for long-acting erythropoietin conjugate |
| UA108636C2 (xx) | 2010-02-17 | 2015-05-25 | Пептид | |
| RS59978B1 (sr) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals Inc | Stabilne formulacije linaklotida |
| DK2776055T3 (en) | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
| EA022327B1 (ru) * | 2013-01-04 | 2015-12-30 | Общество С Ограниченной Ответственностью "Рубикон" | Инъекционное ветеринарное средство в форме раствора для борьбы с полиинвазиями животного и способ его получения |
| US10052361B2 (en) | 2014-03-29 | 2018-08-21 | Intas Pharmaceuticals Ltd | Liquid pharmaceutical composition of conjugated erythropoietin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3865801A (en) * | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| AU593794B2 (en) * | 1985-03-06 | 1990-02-22 | Survival Technology Inc. | Protein absorption enhancing agent |
-
1987
- 1987-09-05 DE DE19873729863 patent/DE3729863A1/de not_active Withdrawn
-
1988
- 1988-08-30 DK DK198804831A patent/DK174811B1/da active
- 1988-08-30 NZ NZ225975A patent/NZ225975A/en unknown
- 1988-08-30 DD DD88319317A patent/DD273004A5/de unknown
- 1988-08-31 IL IL87628A patent/IL87628A/xx not_active IP Right Cessation
- 1988-08-31 MX MX1288088A patent/MX12880A/es unknown
- 1988-09-01 AT AT88114246T patent/ATE77556T1/de not_active IP Right Cessation
- 1988-09-01 EP EP88114246A patent/EP0306824B1/de not_active Expired - Lifetime
- 1988-09-01 CS CS590188A patent/CS274681B2/cs not_active IP Right Cessation
- 1988-09-01 US US07/240,005 patent/US4992419A/en not_active Expired - Lifetime
- 1988-09-01 DE DE8888114246T patent/DE3872334D1/de not_active Expired - Lifetime
- 1988-09-01 ES ES88114246T patent/ES2051806T3/es not_active Expired - Lifetime
- 1988-09-01 PL PL1988274485A patent/PL157944B1/pl unknown
- 1988-09-02 NO NO883926A patent/NO178687C/no not_active IP Right Cessation
- 1988-09-02 PH PH37498A patent/PH25618A/en unknown
- 1988-09-02 IE IE267188A patent/IE60310B1/en not_active IP Right Cessation
- 1988-09-02 FI FI884051A patent/FI93517C/fi not_active IP Right Cessation
- 1988-09-02 CA CA000577075A patent/CA1330301C/en not_active Expired - Lifetime
- 1988-09-02 PT PT88417A patent/PT88417B/pt not_active IP Right Cessation
- 1988-09-02 AU AU21739/88A patent/AU610636B2/en not_active Expired
- 1988-09-02 ZA ZA886528A patent/ZA886528B/xx unknown
- 1988-09-02 HU HU884536A patent/HU202761B/hu unknown
- 1988-09-05 CN CN88106464A patent/CN1027224C/zh not_active Expired - Lifetime
- 1988-09-05 RU SU884356379A patent/RU2043118C1/ru active
- 1988-09-05 UA UA5010234A patent/UA26855C2/uk unknown
- 1988-09-05 JP JP63220591A patent/JPH0780782B2/ja not_active Expired - Lifetime
- 1988-09-05 KR KR1019880011488A patent/KR960009929B1/ko not_active IP Right Cessation
- 1988-09-05 UA UA4356379A patent/UA26123A/uk unknown
-
1991
- 1991-12-02 RU SU915010234A patent/RU2100032C1/ru active
-
1992
- 1992-08-20 GR GR920401275T patent/GR3005454T3/el unknown
-
1993
- 1993-06-02 LV LVP-93-470A patent/LV10178B/lv unknown
-
1995
- 1995-06-08 HK HK89495A patent/HK89495A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV10178B (en) | Method of preparation of physiologically acceptable, stable in storage protein composition | |
| EP0510949B2 (en) | Cytomodulating conjugates of members of specific binding pairs | |
| KR950014915B1 (ko) | 탈시알로당단백-포함화합물 | |
| Andreasen et al. | Purification of a novel calmodulin-binding protein from bovine cerebral cortex membranes | |
| US9714292B2 (en) | Bispecific antibodies against human TWEAK and human IL17 and uses thereof | |
| Ray et al. | Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome | |
| AU700788B2 (en) | Liquid immunoglobulin formulations | |
| IE66223B1 (en) | Recombinant pseudomonas exotoxin construction of an active immunotoxin with low side effects | |
| HK1151045A1 (en) | Liquid immunoglobulin g (lgg) product g(lgg) | |
| Jacob et al. | Abnormal haem binding and globin SH group blockade in unstable haemoglobins | |
| WO2014161570A1 (en) | Antibodies against human il17 and uses thereof | |
| JPS60172923A (ja) | シスジクロロジアンミン白金を含有する安定な注射液に適した水溶液 | |
| EP0998942A1 (en) | Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method | |
| GB9200247D0 (en) | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation | |
| EP0003150B1 (en) | Stabilized aqueous parenteral antibiotic compositions and a process for their preparation | |
| CA1094452A (en) | Solution and substance for the preparation thereof | |
| SE460638B (sv) | Suppositoriepreparat med foerbaettrad absorptionsegenskap | |
| US4966774A (en) | Superoxide dismutase composition | |
| CA2005119A1 (en) | Use of basic amino acids to solubilize immunoglobulins | |
| KR860000072A (ko) | 임균 예방 백신의 제조방법 | |
| EP0972520A1 (en) | Freeze-dried composition of bone morphogenetic protein human mp52 | |
| AU727797B2 (en) | Process for isolating IgG and IgA | |
| CA2136438A1 (en) | Anthracycline conjugates, their preparation and their use as antitumor agents | |
| Distler et al. | [41] Low molecular weight phosphomannosyl receptor from bovine testes | |
| GB2224744A (en) | Detergent compositions |